T he term epigenetics was first used to refer to the complex interactions between the genome and the environment that are involved in development and differentiation in higher organisms. Today, this term is used to refer to heritable alterations that are not due to changes in DNA sequence. Rather, epigenetic modifications, or tags, such as DNA methylation and histone modification, alter DNA accessibility and chromatin structure, thereby regulating patterns of gene expression. These processes are crucial to normal development and differentiation of distinct cell lineages in the adult organism. They can be modified by exogenous influences, and as such, they can contribute to or be the result of environmental alterations of phenotype or pathophenotype. Importantly, epigenetic programming has a crucial role in the regulation of pluripotency genes, which become inactivated during differentiation. Here, we review the major mechanisms in epigenetic regulation; highlight the role of stable, long-term epigenetic modifications that involve DNA methylation; and discuss those modifications that are more flexible (short-term) and involve histone modifications, such as methylation and acetylation. We will also discuss the role of nutritional and environmental challenges in generational inheritance and epigenetic modifications, concentrating on examples that relate to complex cardiovascular diseases, and specifically dissect the mechanisms by which homocysteine modifies epigenetic tags. Lastly, we will discuss the possibilities of modifying therapeutically acquired epigenetic tags, summarizing currently available agents and speculating on future directions.
Chromatin is the complex of chromosomal DNA associated with proteins in the nucleus (for review, see Campos and Reinberg 1 ). DNA in chromatin is packaged around histone proteins, in units referred to as nucleosomes. A nucleosome has 147 base pairs of DNA associated with an octomeric core of histone proteins, which consists of 2 H3-H4 histone dimers surrounded by 2 H2A-H2B dimers. N-terminal histone tails protrude from nucleosomes into the nuclear lumen. H1 histone associates with the linker DNA located between the nucleosomes. Nucleosome spacing determines chromatin structure, which can be broadly divided into heterochromatin and euchromatin (Table 1) . 1, 2 Chromatin structure and gene accessibility to transcriptional machin-ery are regulated by modifications to both DNA and histone tails (Figure 1 ).
Epigenetic Tags: Acquisition, Maintenance, and Inheritance

DNA Methylation
In differentiated mammalian cells, the principal epigenetic tag found in DNA is that of covalent attachment of a methyl group to the C5 position of cytosine residues in CpG dinucleotide sequences (referred to as CpG throughout this review). 3 Recent findings suggest that in undifferentiated stem cells, cytosines other than those in CpG can be methylated as well 4 and that methylation of non-CpG cytosines is crucial for gene regulation in embryonic stem cells in particular. CpG methylation is, however, an important mechanism to ensure the repression of transcription of repeat elements and transposons, and it plays a crucial role in imprinting and X-chromosome inactivation. 5 Transcriptional gene silencing by CpG methylation also restricts the expression of some tissue-specific genes during development and differentiation by repressing them in nonexpressing cells. During development, the pattern of CpG methylation changes in a predictable manner. In early embryogenesis, methylation is erased throughout the genome and then reestablished in all but CpG islands (regions of the genome with a concentration of CpG residues). CpG islands remain hypomethylated until later in development, when some of them become methylated. 6, 7 Subsequent methylation of cytosines in CpG islands and at other CpG dinucleotides is associated with transcriptional repression, 6, 8 especially when these methylated sites involve promoter or other gene regulatory regions. 3 DNA methylation may, however, be activating if it prevents binding or limits expression of transcriptional repressors. Recent studies defining the degree of methylation in mammalian promoters indicate that methylation occurs at only a small percentage of CpG dinucleotides and inhibits transcription of only a small subset of genes in differentiated cells. Many of these repressed genes are germline specific, 8 including pluripotency genes, which suggests that methylation is a crucial mechanism by which key genes are suppressed during differentiation. 8 CpG methylation can suppress transcription by several mechanisms. First, the presence of the methyl group at a specific CpG may directly block DNA recognition and binding by some transcription factors. For example, several studies have shown that transcriptional activation at GC boxes is inhibited by methylation, which excludes binding of Sp1 and Sp3 transcription factors, at least in some promoter contexts. 9, 10 Methylation has also been shown to block the ability of the nuclear factor Hif1 to induce erythropoietin transcription under hypoxic conditions. 11 Alternatively, other factors may preferentially bind to methylated DNA, blocking transcription factor access. For example, MeCP2 (methyl CpG-binding protein 2) and other family members 12 bind to methyl CpG and contribute to transcriptional repression by the recruitment of histone-modifying proteins, such as histone deacetylases (HDACs). Subsequently, histone deacetylation promotes chromatin condensation, which further represses transcription. 13, 14 This sequence of events illustrates how DNA methylation and certain histone modifications function together to contribute to the transcriptional on or off state of genes subject to epigenetic modification ( Figure 1 ).
A family of DNA methyltransferase enzymes (DNMTs) is involved in de novo DNA methylation and its maintenance. During embryogenesis, de novo methylation is performed by DNMT3A and DNMT3B. 15 Although some studies suggest an ongoing role for DNMT3A and DNMT3B in maintaining methylation status in some cell types, 16, 17 the ubiquitously expressed DNMT1 is predominantly responsible for maintaining cellular levels of CpG methylation. Interestingly, transcription from alternative promoters results in expression of a truncated oocyte-specific DNMT1 isoform, DNMT1o, that is essential for early embryogenesis. 18 DNMT1 functions in a complex to recognize hemimethylated DNA and to add methyl groups to the nonmethylated daughter strand formed during replication. 19 The base pairing of CpG allows for the reciprocal maintenance of methylation during subsequent replication cycles. In this manner, a nongenetic trait (DNA methylation) can be passed from cell to cell, and with it, the contextual effects on gene expression. Thus, methylation can be considered a long-term, relatively stable epigenetic trait, the effects of which can contribute to maintenance of the cellular phenotype.
Targeting DNA Methylation: Role of Histone Modification, DNA-Binding Proteins, and RNA
Owing to its heritability, DNA methylation is a powerful means by which to suppress the expression of unwanted or excess genes. Several basic questions remain unanswered, such as the mechanisms that promote targeting of specific CpG sites for methylation or prevent their modification. Many of the insights into the mechanistic aspects of targeting CpG methylation come from studies of imprinting and X-inactivation, by which CpG methylation represses gene expression in chromosomal regions. X-inactivation occurs in somatic cells of females to limit the expression of most X-chromosome genes to those from 1 chromosome. Given the random nature of X-chromosome inactivation, women carriers may display a wide variation in phenotypic expression of X-linked disorders. 20 Similarly, imprinting regulates autosomal gene expression to genes from only 1 parental allele in men and women. The importance of imprinting and gene-dosage regulation in normal development can be appreciated by the consequences of imprinting disturbances that cause a number of human syndromic disorders, such as Prader-Willi, Angelman, Silver-Russell, and Beckwith-Wiedermann (reviewed in Butler 21 and Feinberg 22 ).
In imprinting, clusters of genes in a chromosomal region are coordinately inhibited by methylation of an imprinting center; these centers are also referred to as differentially methylated regions, and they often overlap CpG islands. Recent studies suggest that transcription of differentially methylated regions in the oocyte may target them for subsequent CpG modification by maintaining an open chromatin structure accessible to de novo methylation. 23 In both imprinting and X-inactivation, the expression of long noncoding RNAs, 24 such as the Xist transcript (X inactive-specific transcript) in X-chromosome inactivation, 25 may also play a regulatory role. Chromatin conformation is apparently essential for the imprinting of some maternally determined imprinted genes. In particular, histone H3-lysine 4 (H3K4) demethylase (lysine-specific demethylase-1 [LSD1]) has been found to be essential for these processes, and deficiency of this enzyme results in embryonic stem cell lethality during early differentiation. 26, 27 To date, the mechanisms involved in specifying methylation of differentially methylated regions during imprinting include recognition of specific DNA sequence motifs in imprinting centers, the expression of factors that are oocyte specific to mark maternal chromosomes, chromatin remodeling, or combinations of these events. Similar mechanisms may also target methylation of specific gene promoters during differentiation.
CpG methylation is erased in a predictable manner during gametogenesis and after zygote fertilization. Recent findings suggest that these processes require the action of cytidine deaminases, such as AID (activation-induced deaminase), as well as DNA repair mechanisms. 28, 29 Thus, enzymatic deamination of 5-methylcytosine leads to formation of thymine and T:G base-pair mismatches: Base excision repair mechanisms subsequently delete thymine and restore C:G base pairing during epigenetic reprogramming. Spontaneous deamination of 5-methylcytosine also requires base excision repair mechanisms to repair base-pairing mismatch, a process that is highly inefficient in most differentiated cells. Thus, spontaneous deamination of 5-methylcytosine has resulted in an overall depletion of CpG dinucleotide sequences in mammalian genomes (over evolutionary time). 30 In differentiated adult cells, CpG methylation is considered long-lasting and refractory to elimination, except by alterations in the expression or activity of DNTM1 ( Figure 2 ) or after spontaneous deamination and mismatch repair. Recently, however, a novel mechanism that involves specific DNA demethylation in response to hormone stimulation has been discovered. 31 In this system, the cytochrome p45027B1 gene (CYP27B1) is repressed by vitamin D-interacting repressor-mediated recruitment of DNA methylases and MBD4, a methyl DNAbinding protein. Transcriptional suppression can be relieved by parathyroid hormone-induced demethylation of promoter CpGs. In the presence of parathyroid hormone-induced phosphorylation, MBD4 can mediate demethylation of promoter CpGs through a base excision repair mechanism that removes methylcytosine, apparently without deamination. This hormone-induced mechanism contrasts with excision repair mechanisms described above in that it is targeted to a specific promoter by hormone action and does not require deamination 32 (Figure 2 ). Other recent studies suggest a role for DNMT3 in active demethylation at estrogen receptor-␣-responsive promoters that also exhibit hormone-induced alterations in CpG methylation status. 33, 34 Although further studies are needed to confirm these mechanisms, the concept of hormone-induced methylation switching adds a new twist to epigenetic regulation. It remains to be seen whether other genes can be similarly regulated by methylation switching that uses these or other as yet unknown mechanisms.
Histone Regulation: Readily Reversible Epigenetic Changes
DNA methylation tags promote the persistence of certain histone states, such as deacetylation, thus providing a mechanism for perpetuating posttranslational histone modifications. Histones can be posttranslationally modified to restructure chromatin in many ways, including by phosphorylation, ubiquitination, acetylation, and methylation. 35, 36 In fact, the histone code hypothesis suggests that different combinations of histone modifications may regulate chromatin structure and transcriptional status. 37, 38 Details, such as the location of nucleosomes relative to the transcriptional start site of a gene, together with specific combinations of sites, types, and extents of histone modifications, add to the complexity of the histone code (reviewed in Campos and Reinberg 1 and Volkel and Angrand 39 ). Nonetheless, efforts have been made to characterize patterns of histone modifications that contribute to cell-type-specific regulation of genes in differentiated cells, such as those associated with smooth muscle-specific genes regulated by serum response factor binding to the CArG box. 40 Of the many described histone modifications, histone acetylation at the -amino group of lysine residues in H3 and H4 tails is most consistently associated with promotion of transcription. However, this description oversimplifies a complex process, because acetylated, open-chromatin structure may also allow access of transcriptional repressors. For example, some bromodomain-containing factors, such as BRG1 and Brd4, are targeted to acetylated histones where they can mediate the formation of repressor (or activator) complexes. 41, 42 Acetylation is targeted to regions of chromatin by the recognition and binding of DNA sequence-specific transcription factors that recruit one of a growing family of histone acetyl transferase cofactors such as CREB-binding protein (CBP) and p300, MYST, and GNAT acetyl transferases (see Table 2 for a list of histone-modifying enzymes). 43 Disruption of the normal acetylation activity of CBP/p300 family members is associated with Rubinstein-Taybi syndrome, an autosomal dominant syndrome, 44, 45 which highlights the importance of these cofactors in regulating the proper expression of gene combinations important in development and differentiation. DNA methylation and demethylation. DNA methylation at the cytosine in CpG dinucleotides is initiated de novo by the DNA methyl transferases (DNMT) 3A and 3B. After replication, DNMT1 plays a primary role in maintaining the methylation state in the daughter strands. Demethylation is thought to occur by reduction of DNMT1 activity or by excision repair mechanisms after deamination of methyl cytosine ( me C) to create a T:G mismatch. Recent findings (discussed further in the text) suggest that the methyl-DNA binding protein 4 (MBD4) may mediate demethylation by a hormonally regulated mechanism that does not involve deamination of me C but rather involves the DNA glycosylase activity of MBD4 followed by a base excision repair mechanism.
Deacetylation of histones correlates with CpG methylation and the inactive state of chromatin. There are 4 classes of HDACs, with members capable of deacetylation of histones or other protein targets. 46 These regulatory proteins are themselves subject to regulation by acetylation, phosphorylation, and sumoylation, 47 which can affect their function, subcellular distribution, and protein-protein associations. 48 Several studies suggest that interactions with sequencespecific DNA binding proteins and corepressor complexes can target certain HDAC proteins to histones in a genespecific manner. 49, 50 Histone lysine methylation patterns and their effects on transcription are more complex than acetylation in that some methylation sites are associated with transcriptionally permissive chromatin (euchromatin) and some are repressive, which fosters heterochromatin formation. In addition, -amino groups of lysine residues can be monomethylated, dimethylated, or trimethylated. Overall, the H3K27me3 and H3K9me states are associated with silencing, whereas the H3K4me3 and H3K36me3 states are transcriptionally permissive modifications (see Table 3 for a list of histone methylation sites). Importantly, methylation marks recruit effector proteins that play essential roles in maintaining the transcriptional state of the chromatin; for example, H3K9me recruits HP1, which contributes to heterochromatin formation.
Most histone lysine methyltransferases have an SET homology domain, a vast family of proteins that can be grouped into 7 subfamilies based on their structural similarities. 39 SET1 family members specifically foster active chromatin by methylating H3K4. Other histone lysine methyltransferase families can methylate several histone targets. In addition, some of these methyltransferases have additional domains that specify binding to methylated DNA or to other proteins, such as CBP. 39 Until recently, histone methylation was considered a longterm epigenetic marker, because the only mechanism for its removal was histone turnover; however, recent studies confirm the existence of multiple histone demethylases capable of demethylating histone lysine methyl groups. These enzymes include LSD1, which removes monomethyl or dimethyl groups from H3K4. The trimethylated modification is targeted for removal by the Jumonji C (JmjC) domaincontaining demethylases 51 (Table 2 ). Similar to histone methylases, LSD1 and JmjC family proteins may demethylate histones in a gene-specific manner, directed in part by interactions between demethylases and DNA sequencespecific nuclear factor complexes. In addition, recent studies show that specific histone demethylases may regulate ⑀ amino acid groups of lysines can be monomethylated (me1), dimethylated (me2), or trimethylated (me3).
*Subtypes of enzymes involved in histone lysine acetylation and methylation. androgen-mediated transcriptional responses and osteoblast differentiation. [52] [53] [54] Noncoding RNA, Transcriptional Gene Silencing, and Epigenetic Modifications
As discussed above, long noncoding RNAs play an essential role in imprinting and X-chromosome inactivation. The gene-silencing effects of these long noncoding RNAs and other long noncoding RNAs, such as HOTAIR in the human homeobox loci, are due in part to their recruitment of remodeling complexes, such as the polycomb complex, that foster histone methylation (notably, the inhibitory H3K27me3). [55] [56] [57] In addition, long noncoding RNAs can suppress transcription by other mechanisms, such as by the recruitment of RNAbinding proteins that interfere with histone deacetylation or that exclude TFIID (transcription factor II D) promoter association. 58, 59 There is also a growing literature on the role of small noncoding RNAs and their effects on transcriptional gene silencing. This group of RNAs includes the Dicer-dependent microRNAs and small inhibitory RNAs formed by RNAinterference pathways, as well as the PIWI-interacting RNAs, which are formed in a Dicer-independent manner and specifically associate with the PIWI subfamily of argonaute proteins. Although each of these classes of small noncoding RNAs has been shown to mediate epigenetic DNA and histone modifications, the PIWI-interacting RNAs appear to have a distinct function of repressing transposon expression in germline cells by fostering de novo DNA methylation. 60 A role for small inhibitory RNA in RNA-mediating DNA methylation and transcriptional gene silencing was first discovered in plants, 61 and has been found to exist in many species, including mammals. 62 Recent findings in mammalian cells suggest that synthetic small inhibitory RNAs and endogenous microRNAs that target gene promoters may direct transcriptional gene silencing by recruiting specific argonaute proteins and forming epigenetic remodeling complexes that suppress gene expression by fostering histone deacetylation, histone methylation (H3K9 and H3K27), and DNA methylation. [63] [64] [65] In fact, although the mechanism has not been elucidated completely, Dicer-deficient embryonic stem cells exhibit defects in differentiation that correlate with a loss of de novo DNA methylation and loss of microRNAs, 66 which suggests a role for endogenous microRNAs in regulating necessary epigenetic changes during differentiation. Other studies indicate that some small inhibitory RNAs targeted to TATA-box sequences may block transcriptional initiation without causing epigenetic modifications to histones and DNA. 67 Overall, these studies illustrate the important role of noncoding RNAs in modulating gene transcriptional silencing.
Role of Epigenetic Changes in Cardiovascular Diseases
It has been suggested that epigenetic changes may account for the missing heritability determinants of complex diseases such as atherosclerosis, hypertension, metabolic syndrome, and diabetes that have not been accounted for to date by genetic studies of sequence variation. 68, 69 In a recent study, the influence of parental origin on disease association was examined by following the inheritance of single-nucleotide polymorphisms near known imprinted genes. These results identified 6 single-nucleotide polymorphisms in which parental origin of a gene alters risk. 70 One of these single-nucleotide polymorphisms that was associated with type 2 diabetes mellitus correlated directly with methylation status as well. Thus, these findings suggest that additional non-sequencedependent variations may contribute to heritable traits. Below, we review the relationships between epigenetics and genetics and between epigenetics and nutrition, as well as how these relationships may influence cardiovascular disease.
DNA Methylation and Single-Nucleotide Polymorphisms
Theoretically, single-nucleotide polymorphisms that create CpG sites may be targets for epigenetic modifications, just as loss of these sites will prevent DNA methylation. The consequences of a polymorphism that results in a CpG in the promoter region of the NDUFB6 gene illustrate this intersection between genetic and epigenetic regulation. NDUFB6 is a respiratory chain protein with diminished expression in type 2 diabetes mellitus. In muscle biopsy samples from elderly patients, NDUFB6 expression inversely correlates with the degree of DNA methylation, which suggests that the presence of a CpG site confers more risk for decreased expression (and potentially disease risk) than not having the site. 71 Taken together, these findings support the concept that epigenetic modifications can influence risk in complex diseases. Barker 72 hypothesized that environmental factors in crucial periods of early life (during fetal development, for instance) can influence risks for cardiovascular and metabolic diseases later in life. This concept is supported by a number of studies that have associated low birth weight in human populations with increased risk of cardiovascular disease (see, for instance, reviews in Barker 72 and McMillen and Robinson 73 ). For example, individuals prenatally exposed to famine during the Dutch Hunger Winter (1944 -1945) experienced a higher prevalence of obesity and coronary heart disease as adults than adults born before or conceived after that period. 74 In Barker's seminal work, it was found that low birth-weight babies who survived infancy had an increased risk of coronary heart disease later in life and that increasing birth weight was associated with a graded decrease in risk. 75 In addition, in utero exposure to hypercholesterolemia has been associated with higher incidence and accelerated progression of lesions in humans, rabbits, and mice. 76, 77 Exposure to different behavioral patterns during early postnatal life has also been shown to influence epigenetic modifications in experimental animal models. 78 Thus, it has been suggested that these long-lasting changes arise, at least in part, from epigenetically mediated alterations in gene expression that occur very early in life. 79 With the application of these concepts to human populations, it has been proposed recently that social and environmental stresses during development may influence epigenetic processes that contribute to the adult race-based US health disparities in diseases such as hypertension, diabetes, stroke, and coronary heart disease. 80 More recent studies in animal models have begun to characterize epigenetic modifications that are influenced by the intrauterine environment. For example, feeding a lowprotein diet to pregnant rats causes low birth weight, hypertension, and endothelial dysfunction in the offspring. Studies have shown a role for the renin-angiotensin system in this phenotype, because treatment of pregnant mothers with angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists 81 alleviates hypertension in the offspring. Consistent with these earlier findings, offspring of pregnant mothers fed low-protein diets were found to have hypomethylated angiotensin II type 1B receptor (AT1bR) gene promoters along with increased adrenal expression of angiotensin II type 1B receptor, 82 which suggests a role for specific hypomethylation in regulating elevated blood pressure in this model. Other studies have reported that a low-protein diet during pregnancy in rat results in overexpression of the hepatic glucocorticoid receptor and peroxisome proliferator-activated receptor-␣ in offspring. 83, 84 Interestingly, it had been reported previously that DNMT1 contains a glucocorticoid receptor response element. 85 These studies established an underlying epigenetic mechanism that involves a decrease in the methylation patterns of glucocorticoid receptor and peroxisome proliferator-activated receptor-␣ promoters, a decrease in DNMT1 expression, and an increase in the levels of transcription-permissive histone modifications. Glucocorticoid receptor and peroxisome proliferator-activated receptor-␣ are key transcription factors, the altered expression of which may modulate the activity of a large number of metabolic pathways, and they have been implicated in the pathology of numerous diseases, including obesity, diabetes, and atherosclerosis. 86, 87 As discussed further in the following section, the methyl group responsible for DNA and histone methylation originates from S-adenosyl methionine (AdoMet) via Met biosynthesis through folate-dependent or -independent pathways of homocysteine (Hcy) remethylation (Figure 3 ). Supplementation of a protein-restricted maternal diet in rats with methyl groups by the addition of folate or glycine has been shown to decrease hypertension, 88 improve endothelium-dependent vasodilation, increase endothelial nitric oxide synthase mRNA levels, 89 and restore both the expression and promoter methylation status of the hepatic glucocorticoid receptor and peroxisome proliferator-activated receptor-␣ receptor in offspring. 83 These data support the hypothesis that folate and other methyl-group donors can influence fetal development and the risk of cardiovascular disease in the next generation. Interestingly, when folate was supplied to the offspring, rather than the pregnant mothers, the methylation status of some but not all of the genes modified by maternal protein restriction increased, 90 which suggests that some epigenetic modifications may not be reversible by nutritional interventions in the offspring.
Epigenetics, Nutrition, and Environment
Other modifiers of methylation may also influence epigenetic tags. For instance, dietary status of choline (a betaine precursor that is involved in folate-independent pathways of methionine synthesis) was shown to affect DNA methylation. 91 Moreover, in a study using apolipoprotein (apo) E-deficient mice to assess the efficacy of dietary intervention in retarding atherogenesis, it was shown that betaine supplementation attenuated atherosclerotic lesion formation and growth. 92 Treatments that alter epigenetic modifications may also have utility in human atherosclerosis, in which DNA methylation changes in target genes such as the estrogen receptor-␣ and -␤ genes 93,94 may contribute to the underlying pathogenic mechanisms (discussed further in Turunen et al 77 ).
Regulation of vascular nitric oxide production by endothelial nitric oxide synthase (eNOS) may influence both atherogenesis and thrombosis. Interestingly, the restricted expression of eNOS to vascular endothelium is determined in part by DNA methylation and histone modifications, 95 because treatment of nonexpressing cell types with a DNMT inhibitor induced demethylation of the eNOS promoter and increased the levels of eNOS mRNA. Furthermore, local enrichment of acetylated H3 and H4 histones across the native eNOS locus was found in eNOS-expressing cells compared with nonendothelial cells, the treatment of which with an HDAC inhibitor upregulated eNOS mRNA expression. Recent data suggest that nitric oxide itself may be an epigenetic factor, on the basis of its regulatory function on chromatin and gene expression, via modification (S-nitrosation and tyrosine nitration) of nuclear factors, HDACs, and histones. 96
Homocysteine: A Link Between DNA Methylation and Vascular Disease
Hcy is biochemically linked to the principal epigenetic tag found in DNA. Although increased circulating levels of Hcy are a risk factor for vascular disease, recent clinical trials that used folate or other vitamin B therapies to lower Hcy failed to reduce cardiovascular event rates, thus casting doubt on the direct causative role of Hcy in vascular disease. 97 Most studies, however, have not explored the consequences of 
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Methionine synthase or Betaine-Hcy Methyltransferase Figure 3 . Homocysteine and methylation reactions. S-adenosylmethionine (AdoMet) is the primary source of methyl groups for hundreds of transmethylases that methylate DNA, RNA, histones, other proteins, and small biological molecules. After transfer of methyl groups, S-adenosyl-homocysteine (AdoHcy) is formed. Accumulation of AdoHcy can inhibit methyltransferases. The hydrolysis of AdoHcy yields homocysteine (Hcy) and adenosine. Intracellular homocysteine can be removed from the cell, reform AdoHcy, become further metabolized in the transsulfuration pathways (not illustrated), or become methylated to form methionine by the folate-dependent methionine synthase or the folate-independent betaine-Hcy methyltransferase.
elevated Hcy on methylation processes, even though Hcy plays a crucial role in methyl-donor biosynthesis. 98 As depicted in Figure 3 , the methyl group responsible for the establishment and maintenance of DNA methylation patterns originates from AdoMet, an intermediate in Hcy metabolism. In addition to DNA methylation, AdoMet serves as the methyl donor for more than 100 different cellular methyltransferase reactions, including histone methylation. After the transfer of the methyl group, AdoMet is converted into S-adenosyl homocysteine (AdoHcy), which inhibits the majority of AdoMet-dependent methyltransferases. AdoHcy is further converted into Hcy and adenosine by AdoHcy hydrolase, which is widely distributed in mammalian tissues. This reaction is reversible, and strongly favors AdoHcy synthesis rather than hydrolysis; however, both Hcy and adenosine are rapidly removed under physiological conditions, which favors the hydrolysis reaction. If Hcy accumulates, AdoHcy will accumulate as well, potentially inhibiting transmethylation reactions. Thus, increased Hcy may be regarded as a global DNA hypomethylation effector via AdoHcy accumulation.
There are many in vivo examples that suggest Hcy levels may modulate global DNA methylation. For example, in healthy humans, increased levels of plasma Hcy were associated with both increased AdoHcy concentrations and DNA hypomethylation in lymphocytes. 99 This inverse relationship between Hcy plasma concentrations and DNA methylation patterns was further confirmed in other reports 100 -102 (with 1 exception 103 ) and extended to several animal models. 102 Several studies support the concept that DNA hypomethylation may be responsible in part for vascular complications associated with increased circulating levels of Hcy. 104 For example, patients with vascular disease manifested increased levels of both plasma Hcy and intracellular AdoHcy, together with decreased DNA methylation, which supports a role for hyperhomocysteinemia in modulating epigenetic mechanisms. 105 This association has also been confirmed in several animal studies in which increased circulating levels of Hcy and AdoHcy were associated with endothelial dysfunction and aberrant DNA methylation patterns. 106 -108 (One human study, however, documented that patients with coronary heart disease had increased global DNA methylation in the presence of elevated serum Hcy levels. 109 ) In patients with renal functional impairment (and altered Hcy clearance), which augments the risk for vascular disease, Ingrosso and colleagues 110 reported increased levels of Hcy together with a reduced global lymphocyte DNA methylation pattern. Of importance, Ingrosso and colleagues 110 reported that global and specific DNA hypomethylation affected the expression of 2 genes (SYLB, a pseudoautosomal gene, and H19, an imprinted gene) and that both global DNA methylation patterns and allelic gene expression were normalized after plasma Hcy levels were lowered with folate administration. Although 2 later reports failed to confirm these observations regarding global hypomethylation in patients with renal failure, 111, 112 the work by Ingrosso and colleagues 110 represents the first human study that causally linked Hcy with altered gene expression via DNA hypomethylation.
Aberrant global DNA methylation is only an index of the potential for epigenetic dysregulation. In addition to AdoHcy, a growing list of factors have been identified that can modify DNA methylation patterns. These include the rate of cell growth and DNA replication, chromatin accessibility, local availability of AdoMet, nutritional factors (including folate supplementation), duration and degree of the hyperhomocysteinemic state, inflammation, dyslipidemias, oxidative stress, and aging. 113 Thus, the relation between increased Hcy and DNA global hypomethylation may be masked in the clinical setting owing to the presence of these confounders, thereby possibly explaining some contradictory and counterintuitive findings reported to date. Another important aspect to consider is that DNA methylation is unequally distributed throughout chromosomes of differentiated cells. 4 Thus, hypermethylated and hypomethylated regions can coexist in the genome, and global DNA methylation status need not correspond to the methylation status of specific genomic regions. For example, it has been shown recently that human cardiomyopathies of different origins display a unifying pattern of altered DNA methylation of 3 angiogenesis-related loci in which the differential (increased or decreased) methylation was correlated with the expression of the corresponding gene. 114 It is likely that research on single-gene methylation and expression may lead to a better understanding of the vascular effects of elevated Hcy. 113, 115 Several investigators have focused on target-gene methylation patterns to explain some of the deleterious effects of Hcy. For example, in cultured endothelial cells, it was shown that Hcy, at physiological relevant concentrations, inhibits cell growth, with a concomitant increase in intracellular AdoHcy concentration and a significant decrease in the AdoMet/AdoHcy ratio, which suggests that cellular hypomethylation could play a role in the observed phenotype. 116 Subsequent studies suggested a role for transcriptional suppression of cyclin A in mediating Hcy-induced endothelial cell growth inhibition 117, 118 and found that Hcy triggers transcriptional inhibition of cyclin A through demethylation of a specific CpG site located in the core promoter, namely, on the cell cycle-dependent element. In addition, cyclin A promoter demethylation eliminates binding of methyl CpGbinding protein 2, which, in turn, impairs HDAC association, which leads to an accumulation of acetylated H3 and H4. The authors concluded that the loss of DNA methylation in the cell cycle-dependent element repressor site and the resulting chromatin remodeling increased chromatin accessibility to repressors, which resulted in inhibition of cyclin A gene transcription. Of additional interest was the observation that a physiological concentration of plasma Hcy inhibited DNMT1 activity in this cell system, which provides evidence that Hcy can directly modulate specific DNA methylation reactions. In other studies, Hcy was also shown to disrupt the growth of endothelial cells by downregulating fibroblast growth factor-2 (FGF2) via an epigenetic mechanism that involves transcriptional repression. 119 Apparently, the FGF2 gene promoter encompasses a CpG island, and in contrast to the cyclin A example, the FGF2 gene was heavily methylated at cytosine residues despite significant AdoHcy accumulation. Normal levels of FGF2 transcription were restored when the cells were simultaneously exposed to a DNA demethylating agent and Hcy. Taken together with other examples in the literature, 108,120 -122 these findings suggest that Hcy and Ado-Hcy accumulation can have complex effects on DNA methylation targets and their transcriptional potential.
Increasing evidence indicates that alterations in lipid metabolism may play a role in vascular pathology associated with hyperhomocysteinemia, [123] [124] [125] [126] and many studies suggest that epigenetics may play a role in these processes. For example, changes in DNA methylation have been suggested as a potential mechanism for altered apoA-I and apoA-IV gene expression in mice with hyperhomocysteinemia. 127, 128 In mice, both apoA-I and apoA-IV genes are contained within the apolipoprotein gene cluster on chromosome 9, and notably, the cluster contains a CpG-rich region that corresponds to the 3Ј flanking region of the apoA-I gene and the 5Ј flanking region of the apoA-IV gene. Similarly, it has been shown that Hcy is significantly and inversely correlated with highdensity lipoprotein-bound cholesterol and apoA-I in both human and murine models of hyperhomocysteinemia. 129 In murine primary hepatocyte cultures, cellular hypomethylation, induced by AdoHcy accumulation, was suggested as an explanation for the Hcy-induced inhibition of apoA-I protein synthesis 130 ; however, additional analysis indicated that Hcy regulation of apoA-I synthesis may also involve other, nonepigenetic mechanisms. Additional evidence for regulation of lipid biosynthesis by the epigenetic effects of Hcy was reported by Devlin and colleagues, 131, 132 who showed that a reduced methylation capacity (assessed by AdoMet/AdoHcy ratio) in liver from mice with mild or moderate hyperhomocysteinemia was associated with hepatic changes in phospholipid species and impaired long-chain polyunsaturated fatty acid metabolism that could be attributed in part to differential CpG methylation of genes involved in these pathways. Taken together, these findings indicate that Hcy may influence gene expression by modulating epigenetic pathways. As discussed above, the list of potential modifiers of methylation is long, which suggests that there are still many questions yet unresolved about the effects of Hcy on methylation, gene expression, and cardiovascular disease risk.
Future Directions and Therapeutic Interventions
The plasticity of certain epigenetic modifications can be followed throughout development and differentiation and in response to environmental stimuli. The fact that modifications can accumulate in aging is supported by studies in genetically identical monozygotic twins: Younger twins were far more concordant in terms of the patterns of DNA methylation and histone acetylation than older twins, which suggests that these tags are acquired or modified over time. 133 Thus, it appears possible that epigenetic modifications may be amenable to pharmacological interventions. For example, 5-azacytidine, a DNMT inhibitor, has been used to increase fetal hemoglobin production by causing hypomethylation of ␥-globin genes in patients with sickle cell disease, 134 and as discussed above, methyl donor treatments (folate, glycine, and betaine) can increase DNA methylation, thereby altering gene expression. Recent studies have also reported a mi-croRNA (microRNA-29b) that can cause global hypomethylation by reducing the expression of DNMT enzymes. 135 These approaches, however, are not specific and may have undesirable consequences on the expression of genes distinct from those of primary interest.
Additional studies are necessary to unravel the mechanisms that select specific genes for epigenetic regulation before targeted therapeutic approaches are developed to reprogram these modifications. To date, most epigenetic therapies have focused on modulating chromatin structure. For example, there has been a surge in the development of many class-and isoform-selective HDAC inhibitors, 136 some of which may have utility in cancer, Huntington disease, sickle cell disease, or cardiovascular diseases. 137, 138 The usefulness of these approaches, again, may depend on the ability of a target HDAC to modulate subsets of genes rather than cause global changes. This goal may not be that unrealistic: sirt6, a sirtuin deacetylase, apparently coordinately regulates the expression of multiple glycolytic genes, 139 which suggests a possible target through which to regulate cellular metabolism. In addition, the specific methylation/demethylation of CYP27B1 31 discussed above suggests novel mechanisms to regulate epigenetic tags at the DNA level by modulating proteins that mediate methylation switching. In addition, small inhibitory RNA-based methods may provide a targeted means to transcriptionally silence genes. Recent findings also suggest that this method may be adapted to provide long-term (with epigenetic changes) or short-term (without epigenetic changes) regulation of gene transcription, depending on the targeting site in the promoter; this type of flexibility may have many therapeutic advantages. 62 Since Waddington made his initial observations about the environmental influences in development, 140 much progress has been made in uncovering the molecular mechanisms involved in epigenetic regulation. At the present time, additional studies are needed to define the human epigenome, its role in development and disease, and the processes that regulate its formation and dynamic modulation throughout the life of an individual.
